This inventor holds 3 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitat Heidelberg. Active years: 2017-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
3 out of 159 
2 out of 64 
Years Active: 2017-2019
Title: Junwei Li: Innovator in Cancer Therapy
Introduction
Junwei Li is a prominent inventor based in Eppelheim, Germany. He has made significant contributions to the field of cancer therapy, particularly through his innovative approaches involving parvoviruses and BCL-2 inhibitors. With a total of 3 patents, his work is paving the way for new treatment options in oncology.
Latest Patents
One of Junwei Li's latest patents focuses on a pharmaceutical composition that combines a parvovirus with a BCL-2 inhibitor. This composition is designed for the treatment of cancer, specifically targeting solid tumors. The preferred inhibitors in this formulation are the BH3 mimetics ABT-737 and ABT-199. This innovative approach highlights the potential of combining viral therapy with targeted molecular inhibitors to enhance cancer treatment efficacy.
Career Highlights
Throughout his career, Junwei Li has worked with esteemed institutions such as the Deutsches Krebsforschungszentrum and Ruprecht-Karls-Universität Heidelberg. His experience in these research environments has allowed him to develop and refine his groundbreaking ideas in cancer therapy.
Collaborations
Junwei Li has collaborated with notable colleagues, including Antonio Marchini and Jean Rommelaere. These partnerships have contributed to the advancement of his research and the development of his patented technologies.
Conclusion
Junwei Li's innovative work in cancer therapy exemplifies the potential of combining viral and molecular therapies to improve treatment outcomes. His contributions are significant in the ongoing fight against cancer, and his patents reflect a commitment to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile